



Susan Uziel-Fusi
Clinical Trial Leader

Novartis Pharmaceuticals
Corporation
One Health Plaza
East Hanover, NJ 07936-1080

Tel 862 778 8300

www.novartis.com

Patrick McLaughlin
Executive Director
ANAHEIM CLINICAL TRIALS
1085 NORTH HARBOR BLVD.
ANAHEIM, CA 92801.

Re: Letter of Assessment for Mr. Jeff De Leon

Dear Patrick,

It is my pleasure to provide a letter of assessment and recognition for Jeff De Leon. Jeff was part of the study team at ACT, which conducted and completed the Novartis study, CNVA237A2101, a thorough Qt study in healthy volunteers.

Jeff was responsible for a great deal of the data entering into the study EDC, until the successful lock of the database.

The study was complex in that many assessments were conducted at many timepoints. The study demanded great attention to detail to enter all pertinent data. The study was further complicated by the Novartis data capture system, which did not work properly for this study. The latter necessitated many rounds of re-entering of the data, and especially at the time of lock, continuous need for re-transmittal of the data to the Novartis server.

Jeff went the extra mile to get it all done and never once complained about the failings of the Novartis EDC tool. Jeff willingly came in every weekend during the study, even during the Thanksgiving holiday, to ensure that all the data would be available for our analysis. He delivered a great effort on behalf of Novartis, and went "above and beyond" any reasonable expectations to work with the Novartis Data Management team in India, which was 13.5 hours ahead. This certainly made communications very cumbersome, but Jeff was able to go with it, and delivered a clean and high quality data set

Jeff showed a great capacity for "making it work", and was a huge plus for our study. I very much appreciated his assistance.

Jeff deserves to be given extra consideration for a job very well done.

Please do not hesitate to contact me if you have any questions.

Sincerely,

A handwritten signature in black ink that reads "Susan Uziel-Fusi". The signature is written in a cursive style with a large initial "S".

Susan Uziel-Fusi
July 31, 2012